Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
56 hedge funds and large institutions have $24.2M invested in Viracta Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 3 closing their positions.
127% more call options, than puts
Call options by funds: $188K | Put options by funds: $83K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
2% more funds holding
Funds holding: 55 → 56 (+1)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
40% less capital invested
Capital invested by funds: $40.4M → $24.2M (-$16.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$306K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$243K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$231K |
| 4 |
FSA
Franklin Street Advisors
Chapel Hill,
North Carolina
|
+$72.2K |
| 5 |
Renaissance Technologies
New York
|
+$50.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$699K |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$58.8K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$40K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$34.1K |
| 5 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$28.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
51
Two Sigma Securities
New York
| – | -$11K | -58 | Closed |
|
52
Citigroup
New York
| – | -$1.97K | -13 | -93% |
|
|
CG
53
Cutler Group
San Francisco,
California
| – | -$152 | -1 | -17% |
|
54
Fifth Third Bancorp
Cincinnati,
Ohio
| – | +$303 | +2 | New |
|
VIRX Hedge Fund Activity: Q1 2016 in Review
56 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2016, worth a combined $24.2M — down 40% from $40.4M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VIRX positions and 3 closed out — a net gain of 1 holder — while 11 added to existing stakes and 15 trimmed.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $306K. The largest seller was Fidelity Investments, cutting an estimated $699K.
- 56 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2016, up from 55 in Q4 2015.
- Funds reported $24.2M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2016, down 40% quarter-over-quarter.
- 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2016 and 3 closed out, a net change of +1 holder.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2016 was DAFNA Capital Management, an estimated $306K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2016 was Fidelity Investments, an estimated $699K sold.
Based on aggregated 13F filings for Q1 2016.